You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Indications and dosage

Varilrix is indicated for active immunisation against varicella of healthy subjects (from the age of 9 months).

Vaccination of susceptible healthy close contacts of subjects at risk of severe varicella is recommended, in order to reduce the risk of transmission of wild-type virus to these patients. Close contacts include parents and siblings of high-risk patients, and medical and paramedical personnel.

Posology and Method of Administration

Children 9 months up to and including 12 years

Two doses (each of 0.5 ml of reconstituted vaccine) should be given to ensure optimal protection against varicella (see section 5.1).

  • Children from 9 to 12 months of age

The second dose should be given after a minimum interval of 3 months.

  • Children from 12 months to 12 years of age

The second dose should be given after an interval of at least 6 weeks but in no circumstances less than 4 weeks.

Varilrix should not be administered to children aged less than 9 months.

Adolescents and adults from 13 years of age and above

Two doses (each of 0.5 ml of reconstituted vaccine). It is preferable to administer the second dose at least 6 weeks after the first dose but in no circumstances less than 4 weeks.

Elderly

There are no data on immune responses to Varilrix in the elderly.

Interchangeability

A single dose of Varilrix may be administered after a first dose of another varicella containing vaccine (see section 5.1).

A single dose of Varilrix may be administered followed by a single dose of another varicella-containing vaccine.

References:

  1. Varilrix SmPC, available at http://www.medicines.org.uk/emc/medicine/9787, last accessed October 2017.

Varilrix is a registered trademark of the GlaxoSmithKline group of companies